17,261 trials
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL · Leukemia Cutis · Recurrent Acute Myeloid Leukemia
Primary: Incidence of Dose-limiting Toxicities (DLTs) (Phase Ib)
Solid Tumor · Non-Small Cell Lung Cancer Recurrent · Hepatocellular Carcinoma Recurrent
Primary: Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab — 300 milligrams (mg)
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities
Cancer · Pain
Primary: Bioavailability of Ketamine — 0; 0; 0; 13.4 ng/mL
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Reduction in Hypertrophic Skin Scarring
Primary: Physician Observer Scar Assessment Score at Week 24 — 0.0; -0.5; 0.8; -0.3 units on a scale — p=1.000
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 38; 31; 30; 98 Participants
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Overall Response — 2; 1; 0; 1 Participants
Primary Alcohol Use Disorder
Primary: Relapse Rates — 13; 15; 14; 18 Participants
Multiple Myeloma
Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657
Migraine in Adolescents
Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days
Prostate Cancer
Primary: Best Objective Response Rate (ORR) — 29.8 Percentage of participants
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants